
    
      An Open-label extension (OLE), expanded access study, to assess long-term safety of
      SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in
      patients who completed study number CHL-AA-201. An exploratory endpoint of Improved safety
      from switching from Zytiga (aberaterone Acetate 1000mg(4 x 250 mg qd) to SoluMatrix™
      Abiraterone Acetate 500mg (4 x 125 mg qd) will also be ascertained..
    
  